Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.

Détails

ID Serval
serval:BIB_13228
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
Périodique
Journal of Clinical Oncology
Auteur(s)
Fokkema E., Groen H.J., Bauer J., Uges D.R., Weil C., Smith I.E.
ISSN
0732-183X
Statut éditorial
Publié
Date de publication
1999
Volume
17
Numéro
12
Pages
3822-3827
Langue
anglais
Résumé
PURPOSE: This multicenter phase II trial was performed to determine tumor efficacy and tolerance of the oral platinum drug JM216 in patients with small-cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with SCLC limited disease unfit for intensive chemotherapy or those with extensive disease received JM216 120 mg/m(2)/d for 5 consecutive days every 3 weeks. Individual dose escalation to 140 mg/m(2)/d was allowed if toxicity was </= grade 2 according to the National Cancer Institute Common Toxicity Criteria. Tumor response was evaluated according to World Health Organization criteria. RESULTS: Twenty-seven patients were assessable for toxicity and 26 for tumor response. Eighty-eight cycles were administered. Common Toxicity Criteria grade 3 and 4 hematologic toxicities were neutropenia in 15.9% and 3.7%, lymphocytopenia in 47.6% and 17.1%, and thrombocytopenia in 19.5% and 10.3% of cycles, respectively. One patient suffered from neutropenic fever. Nausea, vomiting, and diarrhea were the most common nonhematologic toxicities. Except for grade 4 diarrhea in one patient, no grade 4 nonhematologic toxicity was observed. No severe neurotoxicity or nephrotoxicity was observed. Tumor response rate was 10 of 26 (38%; 95% confidence interval, 19% to 58%), excluding five unconfirmed partial responses. No complete responses were observed. Median overall time to progression was 110 days (range, 5 to 624 days). Median overall survival time was 210 days (range, 5 to 624 days). CONCLUSION: Oral JM216 is active in previously untreated patients with SCLC and shows mild toxicities.
Mots-clé
Aged, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Carcinoma, Small Cell/blood, Carcinoma, Small Cell/drug therapy, Female, Humans, Lung Neoplasms/blood, Lung Neoplasms/drug therapy, Male, Middle Aged, Organoplatinum Compounds/adverse effects, Organoplatinum Compounds/therapeutic use, Platinum/blood, Treatment Outcome
Pubmed
Web of science
Création de la notice
19/11/2007 13:04
Dernière modification de la notice
03/03/2018 14:00
Données d'usage